PART I Overview We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-, family of proteins. We are a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart ...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001664710-26-000018 | EDGAR | 105K words |
| 2025-02-26 | 2024-12-31 | 0001664710-25-000018 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001664710-24-000017 | EDGAR | — |
| 2023-03-03 | 2022-12-31 | 0001664710-23-000021 | EDGAR | — |
| 2022-03-09 | 2021-12-31 | 0001664710-22-000011 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001664710-21-000018 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001664710-25-000089 | EDGAR | 68K words |
| 2025-08-06 | 2025-06-30 | 0001664710-25-000070 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001664710-25-000046 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001664710-24-000091 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001664710-24-000068 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001664710-24-000039 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001664710-23-000066 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001664710-23-000050 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001664710-23-000030 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001664710-22-000056 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001664710-22-000040 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001664710-22-000019 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001664710-26-000024 | EDGAR | 1K words |
| 2026-03-04 | 0001664710-26-000021 | EDGAR | — |
| 2026-03-04 | 0001664710-26-000017 | EDGAR | — |
| 2026-02-26 | 0001664710-26-000008 | EDGAR | — |
| 2026-02-18 | 0001664710-26-000005 | EDGAR | — |
| 2026-01-09 | 0001664710-26-000003 | EDGAR | — |
| 2025-11-05 | 0001664710-25-000086 | EDGAR | — |
| 2025-10-15 | 0001104659-25-099512 | EDGAR | — |
| 2025-09-08 | 0001664710-25-000081 | EDGAR | — |
| 2025-08-28 | 0001664710-25-000078 | EDGAR | — |
180 total filings indexed. 152 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001664710 |
| Ticker | KROS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.kerostx.com |
| Listed | 2020-04-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report